Core Viewpoint - TaiLong Pharmaceutical's stock price increased by 3.24% to 7.00 CNY, reflecting positive market sentiment and trading activity [1] Company Overview - TaiLong Pharmaceutical operates in the pharmaceutical manufacturing industry, focusing on three core business segments: drug formulations, traditional Chinese medicine pieces, and pharmaceutical research and development services [1] - The company was established in 1993 and became the first listed pharmaceutical company in Henan Province when it went public on the Shanghai Stock Exchange in 1999 [1] Recent Developments - On August 15, TaiLong Pharmaceutical announced the completion of its board of directors' re-election and the appointment of senior management and securities affairs representatives [1] - The company elected five non-independent directors and three independent directors, with Wang Rongtao being appointed as the chairman of the tenth board of directors [1] - Wang Rongtao has previously held positions as the secretary and chairman of Zhengzhou High-tech Construction Group Co., Ltd., and currently serves as a member of the party branch and vice chairman of Zhengzhou High-tech Science City Investment Development Group Co., Ltd. [1] Stock Performance - The stock opened at 6.73 CNY, reached a high of 7.20 CNY, and a low of 6.64 CNY during the trading session [1] - The trading volume was 548,988 hands, with a total transaction value of 381 million CNY [1]

Core Viewpoint - Tai Long Pharmaceutical announced the approval of multiple proposals, including the cancellation of the supervisory board and amendments to related articles, during its third extraordinary general meeting of shareholders for 2025 [2] Group 1 - The company held its third extraordinary general meeting of shareholders on August 15 [2] - The meeting resulted in the approval of the proposal to cancel the supervisory board [2] - Amendments to related articles were also approved during the meeting [2]

Core Viewpoint - Tai Long Pharmaceutical announced the approval of multiple proposals, including the election of the chairman of the board at the first meeting of its tenth board of directors [2] Group 1 - The company held its first meeting of the tenth board of directors on August 15 [2] - The board approved the proposal for the election of the chairman [2]

Group 1 - The company announced that it will hold a staff representative meeting on August 15, 2025 [1] - Chen Fengyun has been democratically elected as the employee representative director of the company's tenth board of directors [1]

太龙药业（SH 600222，收盘价：7元）8月15日晚间发布公告称，公司第十届第一次董事会会议于2025 年8月15日在公司一楼会议室以现场结合通讯的方式召开。会议审议了《关于聘任公司董事会秘书的议 案》等文件。 2024年1至12月份，太龙药业的营业收入构成为：医药制造业占比79.38%，医药研发占比13.65%，医药 流通占比6.71%，其他业务占比0.27%。 （文章来源：每日经济新闻） ...

Core Points - The board of directors of Henan Tailong Pharmaceutical Co., Ltd. held its first meeting of the tenth session on August 15, 2025, with all nine directors present [1][2][3] - The meeting approved the election of Wang Rongtao as the chairman of the board, with a unanimous vote of 9 in favor [1] - Li Jingliang was elected as the vice chairman of the board, also with a unanimous vote of 9 in favor [2] - The board established various specialized committees, including the Strategy and Development Committee, Audit Committee, Nomination Committee, and Compensation and Assessment Committee, with all members elected unanimously [2] - Li Jingliang was appointed as the general manager of the company, with a unanimous vote of 9 in favor [3] - Su Fengshan was appointed as the executive vice general manager, and three others were appointed as vice general managers, all with unanimous approval [3] - Zhao Hailin was appointed as the financial officer, and Li Nianyun was appointed as the board secretary, both with unanimous votes [4] - Wu Ting was appointed as the securities affairs representative, also with unanimous approval [4]

河南仟问律师事务所关于河南太龙药业股份有限公司 2025 年第三次临时股东大会的法律意见书 仟问律师事务所 CHAINWINLAWFIRM 中国郑州市平安大道 189 号正商环湖国际 5、12 层(450018) 网址(URL)：http://www.chainwinlaw.com 电邮(E-mail):qwlss@126.com 仟见字【2025】371 号 关于河南太龙药业股份有限公司 致：河南太龙药业股份有限公司 河南仟问律师事务所（以下简称"本所"）接受河南太龙药业股份有限公司（以 下简称"公司"）的委托，委派本所律师出席公司 2025 年第三次临时股东大会（以 下简称"本次股东大会"），就本次股东大会的召集和召开程序，出席本次股东大 会人员的资格，审议事项及其表决程序等相关事宜出具法律意见。 为出具本法律意见书，本所律师审查了公司提供的有关本次股东大会的文件、 材料。公司保证其向本所提供的文件和材料是完整、真实和有效的，且一切足以 影响本法律意见书的事实、文件和材料均已向本所披露，无任何隐瞒、疏漏之处。 （以下简称"《公司法》"）、 有鉴于此，本所律师根据《中华人民共和国公司法》 《中华人民共和国证 ...

Meeting Overview - The shareholders' meeting of Henan Tailong Pharmaceutical Co., Ltd. was held on August 15, 2025, at the company's conference room in Zhengzhou High-tech Industrial Development Zone [1] - The meeting was convened by the board of directors and chaired by Chairman Yin Hui, utilizing a combination of on-site and online voting methods [1][3] - All procedures for convening and conducting the meeting complied with the Company Law and the company's articles of association, ensuring the legality and validity of the resolutions [3][4] Voting Results - Non-cumulative voting resolutions were all passed with significant support, including: - A total of 151,054,504 votes (98.4456%) in favor, 1,343,931 votes (0.8759%) against, and 1,041,100 votes (0.6785%) abstaining for the first resolution [1] - Similar high approval rates were observed for subsequent resolutions, with votes in favor consistently above 98% [1][2] - Cumulative voting for the election of directors also showed strong support, with 151,676,834 votes (98.8512%) in favor for the election of non-independent directors [2] Legal Compliance - The meeting's resolutions were confirmed to be legally valid, as they met the required thresholds for special and ordinary resolutions, with over two-thirds and half of the voting rights respectively [3][4] - Legal representatives confirmed that all aspects of the meeting adhered to relevant laws and regulations, ensuring the integrity of the proceedings [4]

Core Viewpoint - The announcement details the election of a new employee representative director, Chen Fengyun, at Henan Tailong Pharmaceutical Co., Ltd., as part of the company's governance structure [1][2]. Group 1: Election Announcement - Henan Tailong Pharmaceutical Co., Ltd. will elect Chen Fengyun as an employee representative director during the third extraordinary general meeting of shareholders in 2025 [1]. - Chen Fengyun will join the eight directors elected at the same meeting to form the company's tenth board of directors, with a term aligned with that board [1]. Group 2: Qualifications of the New Director - Chen Fengyun meets all legal and regulatory requirements for the position of director, with no disqualifications under the Company Law or the company's articles of association [1]. - There are no current restrictions on Chen Fengyun's ability to serve as a director, including any sanctions from the China Securities Regulatory Commission or recognition by stock exchanges as unsuitable for the role [1]. Group 3: Background of Chen Fengyun - Chen Fengyun, born in January 1978, holds a bachelor's degree and is a member of the Communist Party of China, as well as a senior accountant [2]. - She has held various positions within the company, including Deputy Manager of the Planning Audit Department and Director of the Budget and Financial Management Center [2].

证券代码：600222 证券简称：太龙药业 公告编号：临 2025-043 河南太龙药业股份有限公司 关于董事会完成换届选举及聘任高级管理人员、 证券事务代表的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 同日，公司召开第十届董事会第一次会议，完成了第十届董事会 董事长、副董事长、各专门委员会委员的选举及高级管理人员、证券 事务代表的聘任等相关事项。现将具体情况公告如下： 一、公司第十届董事会组成情况 （一）董事会成员 董事长：王荣涛先生 副董事长：李景亮先生 董事会成员：王荣涛先生、李景亮先生、陈四良先生、陈金阁女 士、罗剑超先生、陈琪女士（会计专业独立董事）、刘玉敏女士（独 立董事）、方亮先生（独立董事）、陈风云女士（职工代表董事） （二）董事会专门委员会组成 战略与发展委员会：王荣涛（主任委员）、李景亮、罗剑超 河南太龙药业股份有限公司（以下简称"公司"）于 2025 年 8 月 和三名独立董事，与公司同日召开的职工代表大会选举产生的一名职 工代表董事共同组成公司第十届董事会。 证券代码：600222 证券简称： ...